surged Wednesday after the biopharmaceutical company reported positive results for a Phase 3 trial of a clinical study for its medication, Korsuva, an injection for patients with kidney disease-related itchiness. The Stamford, Connecticut-based company said that dialysis patients experiencing itchiness who were given a Korsuva injection showed statistically significant improvement compared with those on placebo. Chronic kidney disease-associated pruritus (CKD-aP) is is an intractable systemic itch condition that occurs with high frequency and intensity in patients undergoing hemodialysis and peritoneal dialysis, Cara Therapeutics said.